Journal of Oncology / 2019 / Article / Fig 1

Research Article

Oncosuppressive Role of RUNX3 in Human Astrocytomas

Figure 1

(a) Representative results for methylation-specific PCR of RUNX3 gene in different malignancy grade gliomas. M: PCR with primers for methylated RUNX3. U: PCR with primers for unmethylated RUNX3. Positive control: bisulfite converted universal methylated human DNA standard (Zymo Research, USA). Negative control: bisulfite converted normal lymphocyte DNA. Normal: “normal human brain DNA” (Zymo Research, cat. no. D5018). Arrows indicate methylated allele. (b) RUNX3 promoter methylation frequency in different astrocytoma grade. GBM revealed significant increase in RUNX3 gene promoter methylation frequency compared to I-III WHO grade astrocytomas (p<0.001, chi-square test). (c) Kaplan-Meier curves for survival (months) of all glioma patients (n=136) stratified by RUNX3 gene methylation status revealed significantly shorter survival of patients with RUNX3 methylated tumours (Log-rank test, χ2=44.68, df=1, p<0.001).


We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.